# Health, Medical and Research Committee Meeting

## Minutes

**25-26 February 2001 - Lausanne**

### Attendees

<table>
<thead>
<tr>
<th>Name</th>
<th>Initials</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Members</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prof. Ken FITCH</td>
<td>KF</td>
<td>Acting Chair</td>
</tr>
<tr>
<td>Prof. Theodore FRIEDMANN</td>
<td>TF</td>
<td>Member</td>
</tr>
<tr>
<td>Dr. Johann Olav KOSS</td>
<td>JK</td>
<td>Member</td>
</tr>
<tr>
<td>Prof. Klaus MUELLER</td>
<td>KM</td>
<td>Member</td>
</tr>
<tr>
<td>Prof. Eduardo Henrique de ROSE</td>
<td>ER</td>
<td>Member</td>
</tr>
<tr>
<td>Prof. Bengt SALTIN</td>
<td>BS</td>
<td>Member</td>
</tr>
<tr>
<td>Dr Gary WADLER</td>
<td>GW</td>
<td>Member</td>
</tr>
<tr>
<td><strong>WADA Staff</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harri SYVÄSALMI</td>
<td>HS</td>
<td>Secretary General</td>
</tr>
<tr>
<td>Nicki VANCE</td>
<td>NV</td>
<td>Director</td>
</tr>
<tr>
<td>Casey WADE</td>
<td>CW</td>
<td>Director</td>
</tr>
<tr>
<td><strong>Observers/Invitees</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mrs Kristina WIBERG</td>
<td>KW</td>
<td>Prof. Ljungqvist’s Assistant</td>
</tr>
<tr>
<td>Dr Jim STRAY-GUNDERSEN</td>
<td>JS</td>
<td>Presenter for Item 13. In attendance for Items 12 and 13</td>
</tr>
</tbody>
</table>

### Apologies

<table>
<thead>
<tr>
<th>Name</th>
<th>Initials</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Members</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prof. Arne LJUNGQVIST</td>
<td>AL</td>
<td>Chair</td>
</tr>
<tr>
<td>Prof. Christianne AYOTTE</td>
<td>CA</td>
<td>Member</td>
</tr>
<tr>
<td>Prof. Barbara DRINKWATER</td>
<td>BD</td>
<td>Member</td>
</tr>
<tr>
<td><strong>WADA Staff</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr Alain GARNIER</td>
<td>AG</td>
<td>WADA Medical Consultant</td>
</tr>
</tbody>
</table>
1. **MEETING COMMENCEMENT**

The Acting Chair, KF opened the meeting at 9.15am.

Apologies from the members and staff listed above were received.

The Chair, AL, sent his apologies via a letter informing the Committee that he was sick but would be available for any necessary consultation during the meeting. Contact was made with AL during the meeting and after both days’ sessions.

2. **APPROVAL OF PREVIOUS MEETING MINUTES**

All Committee Members approved the minutes from the last meeting held on 15-16 October 2000 in Lausanne in full. (Minor amendments to attendee list and name spelling only)

Moved by GW, seconded by ER.

3. **REPORT BY CHAIRMAN**

AL had forwarded a report which was tabled

4. **UPDATE ON CURRENT STAFF**

HS updated group on existing and proposed new staff.

- Casey WADE has been a consultant/Director for WADA since 1 Dec. 2001
- Nicki VANCE has been a Director for WADA since 15 January 2001
- Shannan WITHERS has been a Project Assistant for WADA since 1 Feb. 2001
- Alain GARNIER is working two days per week as a Medical Consultant, seconded from the French Government.
- Olivier NIGGLI will start working for WADA as a fulltime Legal Adviser on 1 March 2001

WADA expects to recruit at least 3 new staff in the near future:
- 1 Government liaison - 1 Assistant – 1 IT Director

5. **KEY WORK OF OTHER WADA COMMITTEES AND STAFF**

5.a **Projects/Issues – briefing by HS**

- HS updated on Evaluation Committee for WADA Permanent Headquarters and Out-of-Competition Testing Tender Process

- HS briefed the Committee on the Nordic Ski positive test during the World Championships in Lahti, Finland, and on the follow-up of testing of most of the Finnish team.
- It is understood that only 2 laboratories are able to test the substance - Hydroxyethyl Starch (HES) found at the World Championships: Cologne Laboratory and Helsinki Laboratory. This was acknowledged as an issue of concern, and KM asked that a recommendation to commence implementing the test be passed on to all the labs as soon as possible

- Salt Lake City Olympic Winter Games:
  - There are expected to be 2 teams: the Independent Observers and the WADA Office/Media team
  - WADA has met with SLOOC Doping Control Team and discussed particularly about the need for coordination of Out-of-Competition Testing prior to the Games

- JK supported the need for an agreement between the International Olympic Committee (IOC) and WADA regarding Out-of-Competition Testing. JK informed the Committee that the IOC has determined that the lab for SLOOC will be the Los Angeles (LA) Laboratory, but set up in Salt Lake City.

- Don YAEGER, Journalist for Sports Illustrated, would be at the WADA office on Monday 26th February afternoon following the meeting to interview members about the work of the Committee, in particular the gene manipulation issue.

**ACTION:**

5.1 WADA to follow up re recommendation to all laboratories to commence testing for HES. - NV

5.b **Athlete Passport**

JK briefed the Committee, and provided a trial presentation on the “Athlete Passport”. The Committee provided some feedback to amend the presentation and generally supported the development of the Project.

There were some concerns regarding the appropriate name of “Athlete Passport”.

5.c **Development of WADA Code - Update**

CW briefed the Committee on the need for coordination of the development of the Code, provided the Committee with the proposal to go to the Executive Committee regarding the establishment of a Code Coordination Committee, and asked that one member of the H,M&R Committee be identified to join this Coordination Committee.

The Committee proposed AL to be the representative for Health, Medical & Research Committee. The Committee suggested some small amendments to the Executive Committee proposal and supported the document and the process.
6. TERMS OF REFERENCE

CW presented a draft Terms of Reference and asked for feedback from the Committee. There was some brief discussion re small amendments, primarily the need for the Board to approve the membership of each of the Working Committees.

**ACTIONS:**

6.1 CW to continue work on the terms of reference of this (and other) Committees for review at May meeting. - CW

7. RESEARCH APPLICATIONS

7.a Decision on the Evaluation Procedure

BS confirmed that the Executive Committee would determine the final decisions regarding the grants, on recommendation from this Committee.

It was agreed that some principles for an objective process would need to be developed. In any case, it was agreed that BS would review all applications and take out any poor or irrelevant applications. Each proposal would need to be considered by at least three people.

7.b Identify Ad-hoc Scientific Reference Group

BS updated the Committee on the status of Ad-hoc Scientific Reference Group. BS wanted to retain involvement of Health, Medical & Research Committee. He proposed one person for each of the three areas from this Committee, and these people will then identify other members to assist in evaluating applications:

1. Prof. Theodore FRIEDMANN (TF) – (Growth factors)
2. Prof. Bengt SALTIN (BS) – (Oxygen carrying factors)
3. Prof. Klaus MUELLER (KM) – (Endogenous factors)

Any proposal regarding the membership of each evaluation group should be sent to the relevant “Team Leader” and to BS who will advise WADA Head Office of the final names.

Once WADA head office has received the names invitation letters would be sent to them from WADA head office. Honorarium may be provided to the reviewers.

The Committee recognised the need to develop a pool of experts on an ad-hoc and ongoing base to provide advice for this and other projects.

7.c General Issues

HS tabled Peter Sonksen e-mail, seeking support for his application to the European Commission for research funding.

The Committee agreed that BS would respond to Peter Sonksen on behalf of WADA, agreeing to support his application but not committing any funding. His application for funding under the grant application process would of course be welcomed.
7.d Time Frame

If possible, reviewers to be identified prior to 2nd April. If necessary, BS to come to
Lausanne on 2nd April to examine applications. Reviews to be completed prior to May
meeting.

**ACTIONS:**

7.1 BS to develop evaluation principles/process with the three team leaders- BS
7.2 BS to review all applications and make first cut - BS
7.3 Members to identify potential reviewers and advise BS - All.
7.4 BS to advise Head Office of final names - BS
7.5 Head Office to send out invitation letters to reviewers – HS/NV
7.6 Members to consider other names for an ongoing pool of experts - All
7.7 BS to respond to Peter Sönksen - BS

8. THERAPEUTIC USE OF PROHIBITED SUBSTANCES

8.a Review proposed name, membership and role of group

KF outlined the background of the need for therapeutic use approval process, and
provided information about some of the existing national Therapeutic Approval
committees.

The Committee discussed the possible jurisdiction and role of a “WADA
Therapeutic Use Subcommittee”.

It was agreed that WADA would establish guidelines and make the Committee
available to IFs, NOCs, NADOs, etc. that require assistance. WADA would then
review the role and jurisdiction of the Committee/WADA during the development of
WADA Code.

KF consulted with the Chair during a break and together proposed 4 Members to
establish a Therapeutic Use Subcommittee: It was resolved to appoint a small
group and seek advice from additional experts from within or outside the
Committee if required.

1. Prof. Arne LJUNGQVIST (AL)
2. Prof. Ken FITCH (KF)
3. Prof Klaus MUELLER (KM)
4. Prof. Gary WADLER (GW)

**ACTIONS:**

8.1 WADA’s Therapeutic Use Subcommittee to establish guidelines
8.2 Once developed WADA to notify IFs, NOCs, NADO, etc. of the existence of
the Subcommittee – AL/NV
8.3 Subcommittee to review the role and jurisdiction of the Committee/WADA
during the development of WADA Code.
8.4 Subcommittee to meet in Stockholm on Saturday 26th May
9. **BANBURY CENTRE GENETIC/SPORT WORKSHOP UPDATE (TF)**

9.a **Review draft invite list**

The Committee reviewed the principles behind who would be invited. TF informed the group that he was in the process of identifying 10 experts from the genetic field.

It was agreed that the H, M & R Committee would all be invited and that WADA would identify the additional names to a total maximum of 35, including representatives from other WADA committees, sport etc. It was acknowledged that it was important that the people invited actually participated in the workshop, not be an audience.

The names would be provided to the Banbury staff (Mr Witkowski) by the end of March.

9.b **Identify draft Workshop Program**

The date of the Workshop was confirmed: 23-26 September 2001 (2 ½ day meeting), (with H,M&R meeting on 23 September, arriving 22 September)

The maximum number of participants is 35, plus WADA staff.

TF provided background to Banbury Workshop, and outlined the general areas to be covered:

- Technical Session
- Pharmacology – Doping
- Genetics / Gene transferring
- Gene Therapy protocols

A preliminary draft program was identified (see attached) with TF agreeing to further develop the program.

The Outcomes are:

- To facilitate a dialogue between the Genetic and Doping fields, based on ethical and medical fields
- To identify the scope of the issue for sport
- To identify potential methods of detection of genetic manipulation
- To develop a monologue statement on the position of the workshop participants/WADA
- To identify follow-up actions

9.c **Identify Ad-hoc Workshop Planning Committee**

TF, GW and WADA staff

**Tasks/Issues**

Need to identify what tasks the Banbury organisers do and what WADA needs to do

Need to identify the budget required.
  - TF will confirm Banbury costs
Need to identify how we will handle the Media as it is expected that there will significant media interest. It was acknowledged that we would not want media present during the workshop or at the workshop centre – this is contrary to the workings of this centre. It is likely that we will need to organise some form of media briefing after the workshop either in another area of Cold Spring Harbour or New York City. WADA would take responsibility for this.

**ACTIONS:**

9.1 List of names to be provided to Banbury staff by end of March - NV  
9.2 TF to further develop program for discussion at May meeting - TF  
9.3 Need to identify what tasks the Banbury organisers do and what WADA needs to do – TF/NV  
9.4 Need to identify the budget required - NV.  
9.5 TF to confirm Banbury costs – TF  
9.6 Need to identify how we will handle the Media – Isabelle Tornare and Mike Kontos

### 10. 2001 LIST OF PROHIBITED SUBSTANCES

10.a Review 2001 List issue

KF provided background to development and history of IOC List of Prohibited Substances.  
KF outlined issues relating to the 2001 List and the process that now needs to be followed to be in accordance with the Code.

The Committee discussed changes made to the list by the IOC and agreed to all changes except for the removal of terbutaline.

The Committee agreed that it would recommend to the WADA Executive Committee that the List as proposed by the IOC-MC be approved with one exception; to reinstate Terbutaline (permitted with prior notification), through the appropriate process (WADA Board approval and recommendation to the IOC-EB). This process should be achieved as rapidly as possible because of global confusion as to the legality of the circulated List.

**ACTION:**

10.1 The recommendation of the Committee to reinstate Terbutaline as a permitted substance (with notification) should be made to the Executive Committee at its 6 March meeting – NV/KF to prepare.

10.b Discussion Paper from KF and KM

A paper was tabled for discussion the following day and in the review of the list for 2002.
11. **2002 LIST OF PROHIBITED SUBSTANCES**

11.a Review KF/KM discussion paper

KM outlined general philosophy about the concept of “and related substances” within the List and the need to clarify and simplify this issue. The Committee discussed the responsibility and role of WADA in the process of reviewing the list for 2002 List of Prohibited Substances, and the likely increased role during the development of the WADA Code in 2001/2002 for introduction in 2003.

KF outlined general issues relating to the timing of bringing in changes for athletes mid-season

11.b Discuss development of 2002 List

The need to establish a review/drafting Ad-hoc Committee was discussed. A draft process document was tabled, a number of timelines in the document amended, and the Committee agreed that it would make a recommendation to the Executive Committee seeking agreement to establishing a review/drafting committee under the Chair of the H,M & R Chair.

11.c Identify proposed Ad-hoc Committee

The Committee discussed possible Ad-hoc Committee Members, and agreed that the proposed names would be forwarded to Arne for sign-off (pending approval of Executive Committee of this proposed role.)

**ACTIONS:**

11.1 Recommendation to be prepared to go to the Executive Committee re establishing an Ad-hoc Committee – NV/KF/AL
11.2 Pending this agreement, the Chair to establish the Ad-hoc Committee - AL
11.3 NV to forward proposed names to AL for sign-off. - NV
11.4 If approved, the Ad-hoc committee to meet in Stockholm.

12. **EPO TEST STATUS UPDATE**

12.a Update report re Australian and collaborators EPO test

An informal fax from the IOC-Accredited Australian laboratory responding to a number of questions about the status of the EPO test was tabled.

12.b Update report re French EPO urine test

A brief report from the IOC-Accredited French Laboratory outlining the status of the EPO test was tabled.

12.c Discuss possible EPO Validation Workshop for WADA/IOC

The Committee acknowledged that the issue was that the EPO test needed to be expanded to more laboratories rather than validated, which it understood to already be completed. It was acknowledged that there was some confusion surrounding the status of the test and any plans for its expansion.
The Committee will seek further information to confirm the status of the EPO test at the Cologne workshop and other avenues, and to identify the existing or potential opportunities to further expand the use of the blood/urine EPO test throughout additional accredited laboratories.

ACTION:

12.1 WADA to seek clarification at the Cologne Workshop and then determine any further actions

13. PRESENTATION BY JIM STRAY-GUNDERSEN
“SAFE AND FAIR EVENTS (SAFE) PARADIGM”

Jim Stray-Gundersen presented the SAFE Program and sought WADA’s involvement to conduct the program in 4 sports this winter (northern hemisphere) season.

The Committee sort some clarification from points of the presentation and discussed the possibilities for supporting this program.

The Committee acknowledged the work of Jim and his colleagues and the existing and potential use of the program as a deterrent of EPO use. It was agreed that Jim would prepare a proposal to WADA regarding the SAFE Testing Program to be used in the lead up to Salt Lake City.

WADA would also explore the possibility of use of the program with the UCI.

ACTIONS:

JS-G to prepare proposal and present to WADA
Once received WADA to review and consider proposal – HS/NV/CW
WADA to discuss possible interest/involvement with UCI – HS/NV

14. FOOD SUPPLEMENT PUBLICATION RESEARCH PROJECT

There was no update on the Research Project. There was a little uncertainty as to the accuracy of the minutes from the previous meeting and it was agreed that NV would seek clarification from CA

The Committee had a general discussion about the issues relating to the supply and use of supplements. It was proposed and subsequently agreed that WADA should make a statement warning athletes to be careful with the use of substances.

GW and KM to immediately prepare a draft for approval by the Chair – AL, who would issue the statement after the Committee meeting

GW also offered to follow up about the issue with governmental authorities in the US

ACTION:

14.1 NV would follow-up with CA regarding supplement project - NV
14.2 GW would follow-up with US governmental authorities - GW
14.3 GW and KM to prepare a statement regarding the use of supplements - GW/KM (completed during the meeting)
14.4 AL to review draft and issue statement -AL

15. **UCI LETTERS/REQUESTS REGARDING:**

15.a News forms of oxygen-carrying substances – 19 December 2000  
15.b The need for review of current research – 22 December 2001

The Committee reviewed the letters received from Hein Verbruggen, UCI President and generally agreed with his concerns. It was agreed to prepare a response outlining that it was anticipated that the areas of concern he had identified would be included in application for the research grant monies, and these would be regarded as key priorities. That WADA had acknowledge the importance of research into these oxygen-carrying substances and other new products and had committed US$4.5million to find answers.

In response to Mr Verbruggen’s request to identify existing research, it was agreed that the Cologne Workshop, to held from 20-23 March 2001 would be an ideal place to request notification of any existing research being undertaken by the laboratories at the Workshop or of knowledge of any other research. George WALKER, Chair of the WADA Standards and Harmonisation Working Committee and NV would be attending this workshop, along with laboratory members of the Committees.

**ACTION:**

15.1 Respond to Hein VERBUGGEN, UCI President, regarding research priorities etc. – HS/NV  
15.2 Seek research projects from laboratories at the Cologne Workshop – George Walker/NV

16. **CAFDIS PROJECT (CONCERNED ACTION IN THE FIGHT AGAINST DOPING IN SPORT)**

HS presented the fax from the CAFDIS Coordinator inviting WADA to participate in the CAFDIS Project. A number of responses from countries confused about the project were also tabled.

The project was discussed and the Committee determined that it would not endorse WADA’s involvement in the CAFDIS project as outlined.

**ACTION:**

16.1 Committee to advise HS that it does not recommend WADA’s involvement in the CAFDIS Project as outlined
17. **IV FLUID REPLACEMENT FOR DEHYDRATED WEIGHT CLASSIFIED ATHLETES (TBC)**

A letter was tabled from Dr Peter Fricker.

The Committee acknowledged that it should have a role in responding to such issues.

It was agreed that ER would review the rules of sports which involve athlete weigh-ins and the subject discussed at the next Committee Meeting in May 2001.

**ACTION:**

17.1 ER to review rules of sports relating to athletes weigh-ins for May meeting - ER

18. **FORUMS**

The Committee was informed about the following forums involving doping control:

18.a IOC Medical Commission Doping & Biochemistry Subcommission and IOC Accredited laboratory heads – 23 April 2001, Monaco (TBC)

18.b IOC Medical Commission Asthma Workshop – 13 May 2001, Lausanne

18.c IOC Medical Commission – IF Meeting – 14 May 2001, Lausanne

18.d First National Scientific Congress on Nutrition and Athletic Performance – 8-11 August 2001, Edmonton, Canada

web site: athleticsandnutritionweb.doc

Additional forums to note:

Cologne Laboratory Workshop – March 2001

Leipzig Forum - Toxicological Analysis and certainty of conclusions – 1-2 October 2001

It was acknowledged that there is some concern regarding the apparent duplication of the current work of the IOC Medical Commission and WADA, and the desire of WADA to work with the IOC Medical Commission in this transition period.

**ACTION:**

18.1 Health, Medical & Research Committee Members to advise NV on different forums through the world which may provide opportunities for WADA’s attendance or involvement - All
19. ANY OTHER BUSINESS

Membership of Committee: There was a brief discussion regarding the Board request to include representatives from Africa and Asia on each Committee.

The Committee acknowledged that their preference would be to meet the wishes of the Board but at the same time recruit members who have background and experience in areas not already covered by the existing members.

Some names were suggested with members (KM and KF) to follow up and seek further information and CVs about these people.

ACTION:

19.1 Committee members to follow up re CVs of suggested new members and forward to NV for use by AL at ExCo meeting – KM, KF

20. DATE AND VENUE OF NEXT MEETING

The next meeting/s will be held:

1. 27-28 May 2001
   STOCKHOLM, Sweden

2. 23 September 2001
   BANBURY, New-York, USA
   [prior to Workshop 24-26 September]

MEETING CLOSURE

The meeting closed at 12.00pm on 26th February 2001

Prepared by: Nicki VANCE

Date: Lausanne, 1 March 2001
Attachment 1

DRAFT PROGRAM BANBURY – preliminary thoughts

24 September

Setting the Scene

AM

Nature of Doping Problem eg. Dick Pound, Arne Ljungqvist

Current screening, what, who eg. Jordi Segura/Christianne Ayotte

PM

Methods of Genetic Technology
- kinds of vectors
- disease models
- target issues
- detection

25 September

AM

Specific Experiments
- Gene regulation
- EPO results
- IGF 1
- Muscle Growth factors
- Tissue repair

PM

Emerging Technology
- Stem Cells
- Cloning

Review and Regulation of Gene Therapy

26 September

AM

Legal, Ethics and Future
## SUMMARY OF ACTIONS

<table>
<thead>
<tr>
<th>No.</th>
<th>Item</th>
<th>Ref.</th>
<th>Action</th>
<th>Action By</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Key Work of Other WADA Committees and Staff</td>
<td>5.1</td>
<td>WADA to follow up recommendation to all laboratories to commence testing for HES</td>
<td>NV</td>
</tr>
<tr>
<td>2</td>
<td>Terms of Reference</td>
<td>6.1</td>
<td>CW to continue work on the terms of reference of this (and other) Committees for review at May meeting.</td>
<td>CW</td>
</tr>
<tr>
<td>3</td>
<td>Research Application</td>
<td>7.1</td>
<td>BS to develop evaluation principles/process with the three team leaders</td>
<td>BS</td>
</tr>
<tr>
<td>4</td>
<td>Research Application</td>
<td>7.2</td>
<td>BS to review all applications and make first cut</td>
<td>BS</td>
</tr>
<tr>
<td>5</td>
<td>Research Application</td>
<td>7.3</td>
<td>Members to identify potential reviewers and advise All.</td>
<td>All</td>
</tr>
<tr>
<td>6</td>
<td>Research Application</td>
<td>7.4</td>
<td>BS to advise Head Office of final names</td>
<td>BS</td>
</tr>
<tr>
<td>7</td>
<td>Research Application</td>
<td>7.5</td>
<td>Head Office to send out invitation letters to reviewers</td>
<td>HS//NV</td>
</tr>
<tr>
<td>8</td>
<td>Research Application</td>
<td>7.6</td>
<td>Members to consider other names for an ongoing pool of experts</td>
<td>All</td>
</tr>
<tr>
<td>9</td>
<td>Research Application</td>
<td>7.7</td>
<td>BS to respond to Peter Sönksen</td>
<td>BS</td>
</tr>
<tr>
<td>10</td>
<td>Therapeutic Use of Prohibited Substances</td>
<td>8.1</td>
<td>WADA’s Therapeutic Use Subcommittee to establish guidelines</td>
<td>Subcommittee</td>
</tr>
<tr>
<td>11</td>
<td>Therapeutic Use of Prohibited Substances</td>
<td>8.2</td>
<td>Once developed WADA to notify IFs, NOCs, NADO, etc. of the existence of the Subcommittee</td>
<td>AL/NV</td>
</tr>
<tr>
<td>12</td>
<td>Therapeutic Use of Prohibited Substances</td>
<td>8.3</td>
<td>Subcommittee to review the role and jurisdiction of the Committee/WADA during the development of WADA</td>
<td>Subcommittee</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Therapeutic Use of Prohibited Substances</td>
<td>8.4</td>
<td>Subcommittee to meet in Stockholm on Saturday 26\textsuperscript{th} May</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Banbury Centre Genetic/Sport Workshop Update</td>
<td>9.1</td>
<td>List of names to be provided to Banbury staff by end of March</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Banbury Centre Genetic/Sport Workshop Update</td>
<td>9.2</td>
<td>TF to further develop program for discussion at May meeting</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Banbury Centre Genetic/Sport Workshop Update</td>
<td>9.3</td>
<td>Need to identify what tasks the Banbury organisers do and what WADA needs to do</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Banbury Centre Genetic/Sport Workshop Update</td>
<td>9.4</td>
<td>Need to identify the budget required</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Banbury Centre Genetic/Sport Workshop Update</td>
<td>9.5</td>
<td>TF to confirm Banbury costs</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Banbury Centre Genetic/Sport Workshop Update</td>
<td>9.6</td>
<td>Need to identify how we will handle the Media</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>2001 List of Prohibited Substances</td>
<td>10.1</td>
<td>The recommendation of the Committee to reinstate Terbutaline as a permitted substance (with notification) should be made to the Executive Committee at its 6 March meeting</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>2002 List of Prohibited Substances</td>
<td>11.1</td>
<td>Recommendation to be prepared to go to the Executive Committee re establishing an Ad-hoc Committee.</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>2002 List of Prohibited Substances</td>
<td>11.2</td>
<td>Pending this agreement, the Chair to establish the Ad-hoc Committee</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>2002 List of Prohibited Substances</td>
<td>11.3</td>
<td>NV to forward proposed names to AL for sign-off</td>
<td></td>
</tr>
</tbody>
</table>

WADA
WORLD ANTI DOPING AGENCY
<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>2002 List of Prohibited Substances</td>
<td>11.4</td>
<td>If approved, the Ad-hoc committee to meet in Stockholm</td>
<td>Ad-hoc Committee</td>
</tr>
<tr>
<td>25</td>
<td>EPO Test Status Update</td>
<td>12.1</td>
<td>WADA to seek clarification at the Cologne Workshop and then determine any further actions</td>
<td>WADA</td>
</tr>
<tr>
<td>26</td>
<td>Presentation By Jim Stray-Gundersen “Safe and Fair events (safe) paradigm”</td>
<td>13.1</td>
<td>JS-G to prepare proposal and present to WADA</td>
<td>JS-G</td>
</tr>
<tr>
<td>27</td>
<td>Presentation By Jim Stray-Gundersen “Safe and Fair events (safe) paradigm”</td>
<td>13.2</td>
<td>Once received WADA to review and consider proposal</td>
<td>HS/NV/CW</td>
</tr>
<tr>
<td>28</td>
<td>Presentation By Jim Stray-Gundersen “Safe and Fair events (safe) paradigm”</td>
<td>13.3</td>
<td>WADA to discuss possible interest/involvement with UCI</td>
<td>HS/NV</td>
</tr>
<tr>
<td>29</td>
<td>Food Supplement Publication Research Project</td>
<td>14.1</td>
<td>NV would follow-up with CA regarding supplement project</td>
<td>NV</td>
</tr>
<tr>
<td>30</td>
<td>Food Supplement Publication Research Project</td>
<td>14.2</td>
<td>GW would follow-up with US governmental authorities</td>
<td>GW</td>
</tr>
<tr>
<td>31</td>
<td>Food Supplement Publication Research Project</td>
<td>14.3</td>
<td>GW and KM to prepare a statement regarding the use of supplements</td>
<td>GW/KM</td>
</tr>
<tr>
<td>32</td>
<td>Food Supplement Publication Research Project</td>
<td>14.4</td>
<td>AL to review draft and issue statement</td>
<td>AL</td>
</tr>
<tr>
<td>33</td>
<td>UCI Letters / Request regarding: 15.a News forms of oxygen-carrying substances – 19 December 2000</td>
<td>15.1</td>
<td>Respond to Hein VERBUGGEN, UCI President, regarding research priorities etc.</td>
<td>HS/NV</td>
</tr>
<tr>
<td>34</td>
<td>UCI Letters / Request regarding: 15.b The need for review of current research – 22 December 2000</td>
<td>15.2</td>
<td>Seek research projects from laboratories at the Cologne Workshop</td>
<td>George Walker NV</td>
</tr>
<tr>
<td>35</td>
<td>CAFDIS Project (Concerned Action in the Fight against Doping in Sport)</td>
<td>16.1</td>
<td>Committee to advise HS that it does not recommend WADA’s involvement in the CAFDIS Project as outlined</td>
<td>All</td>
</tr>
<tr>
<td>36</td>
<td>IV Fluid Replacement for Dehydrated Weight Classified Athletes (TBC)</td>
<td>17.1</td>
<td>ER to review rules of sports relating to athletes weigh-ins for May meeting</td>
<td>ER</td>
</tr>
<tr>
<td></td>
<td>Forums</td>
<td>18.1</td>
<td>Health, Medical &amp; Research Committee Members to advise NV on different forums through the world which may provide opportunities for WADA’s attendance or involvement</td>
<td>All</td>
</tr>
<tr>
<td>---</td>
<td>----------</td>
<td>------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>37</td>
<td>Any other Business</td>
<td>19.1</td>
<td>Committee members to follow up re CVs of suggested new members and forward to NV for use by AL at ExCo meeting</td>
<td>KM/KF</td>
</tr>
</tbody>
</table>